Mantle Cell Lymphoma

Disease State Hub

Featured

Research Summary
Research Summary
06/19/2026
Ashton L. Stahl
A phase 3 trial-level analysis evaluated whether PFS reliably predicts OS in mantle cell lymphoma.
06/19/2026
Timeline Snapshot
FDA logo on website
Timeline Snapshot
05/29/2026
May 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
05/29/2026
Research Summary
Research Summary
05/14/2026
Anthony Calabro, MA
In an open-label, multicenter phase 2 study, frontline mantle cell lymphoma, MRD-driven acalabrutinib-lenalidomide anti-CD20 therapy produced high molecular complete response rates.
05/14/2026